CADTH launches new RWE program for HTA decision-making

17 Feb 2022

Written by Darcy Hodge, Editor

Health economics Health technology assessment Medical devices, pharmaceuticals and vaccines News Real-world evidence Stakeholder engagement

The Canadian Agency for Drugs and Technologies in Health (CADTH, Ottawa, Canada) has launched a new program to provide more information on drug safety and efficacy. It is part of overall goal to improve HTA decision-making in Canada. The program, termed the Post-Market Drug Evaluation (PMDE) program, will utilize real-world evidence (RWE) to produce approvals such as managed access agreements. President and CEO of CADTH, Suzanne McGurn, stated to the Pink Sheet that the program will assist the HTA “to provide a responsive and systemic approach to delivering post-market evidence.” The PDME program will launch in September, involving the expertise...